Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Corcept Therapeutics (CORT) EBITDA Margin (2016 - 2025)

Historic EBITDA Margin for Corcept Therapeutics (CORT) over the last 13 years, with Q3 2025 value amounting to 4.92%.

  • Corcept Therapeutics' EBITDA Margin fell 206100.0% to 4.92% in Q3 2025 from the same period last year, while for Sep 2025 it was 8.85%, marking a year-over-year decrease of 139600.0%. This contributed to the annual value of 20.29% for FY2024, which is 19500.0% down from last year.
  • According to the latest figures from Q3 2025, Corcept Therapeutics' EBITDA Margin is 4.92%, which was down 206100.0% from 13.72% recorded in Q2 2025.
  • Corcept Therapeutics' EBITDA Margin's 5-year high stood at 32.09% during Q4 2021, with a 5-year trough of 2.17% in Q1 2025.
  • In the last 5 years, Corcept Therapeutics' EBITDA Margin had a median value of 23.39% in 2023 and averaged 22.03%.
  • In the last 5 years, Corcept Therapeutics' EBITDA Margin soared by 68500bps in 2021 and then plummeted by -206100bps in 2025.
  • Corcept Therapeutics' EBITDA Margin (Quarter) stood at 32.09% in 2021, then crashed by -32bps to 21.83% in 2022, then rose by 7bps to 23.39% in 2023, then plummeted by -41bps to 13.89% in 2024, then crashed by -65bps to 4.92% in 2025.
  • Its EBITDA Margin was 4.92% in Q3 2025, compared to 13.72% in Q2 2025 and 2.17% in Q1 2025.